Anti-Japanese Encephalitis Virus (Clone: JEV-75)

Product code: 12-8129

Clone name : JEV-75
Clonality : Monoclonal
Application : ELISA

Shipping Info:

For estimated delivery dates, please contact us at [email protected]

Write a review for this product on BioCompare
Get $20 gift card from Amazon
Size
Price
100 µg
$499.00 

Add to Wish List

Shipping Info:

For estimated delivery dates, please contact us at [email protected]


Amount : 100 µg
Isotype : Human IgG1λ
Purification : ≥95% monomer by analytical SEC
Content : ≥ 5.0 mg/ml Formulation : This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Storage condition : Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Alternative Name : NamesJEV
Immunogen Information : A panel of human mAbs against JEV, including JEV-75, was generated from donors immunized with a GIII vaccine strain (JEV-SA14-14-2)
Reactivity Species : Japanese Encephalitis-Virus
Expression Host : HEK-293
Endotoxin Level : ≤ 1.0 EU/mg as determined by the LAL method
Specificity : JEV-75 activity is directed against the E ectodomain, but not to E-DI or E-DIII. Furthermore, this human Mab showed no cross-reactivity to West Nile Virus or Zika Virus E proteins.
JEV-75 binds to the E ectodomain but not to DI or DIII. Alanine scanning mutagenesis at sites corresponding to the E ectodomain cause loss-of-binding at S275 in the DI-DII-hinge region, L180 in the DI-LR, N82 in the DII-LR, W217 in the DII-central interface, and DIII residue F308 in the A-strand epitope.
Background : Japanese Encephalitis Virus (JEV) is a mosquito-borne, enveloped, positive-stranded RNA virus in the Flavivirus genus endemic to Asia and parts of the western Pacific1. Symptomatic JEV infection is most common in children in areas of endemicity or travellers to those regions. Severe symptoms occur in ~1% of cases, with a case-fatality ratio of 20–30%. Survivors often have serious neurologic, cognitive, or psychiatric sequelae. Five JEV genotypes have been identified and existing vaccines are derived from historically predominant GIII strains.
 
There are currently no product reviews

Customers who purchased this product also purchased

Most viewed Products